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Wnt5A activates the calpain-mediated cleavage of filamin A
Abstract
We have previously shown that Wnt5A and ROR2, an orphan tyrosine kinase receptor, interact to
mediate melanoma cell motility. In other cell types, this can occur through the interaction of ROR2 with
the cytoskeletal protein filamin A. Here, we found that filamin A protein levels correlated with Wnt5A
levels in melanoma cells. Small interfering RNA (siRNA) knockdown of WNT5A decreased filamin A
expression. Knockdown of filamin A also corresponded to a decrease in melanoma cell motility. In
metastatic cells, filamin A expression was predominant in the cytoplasm, which western analysis
indicated was due to the cleavage of filamin A in these cells. Treatment of nonmetastatic melanoma
cells with recombinant Wnt5A increased filamin A cleavage, and this could be prevented by the
knockdown of ROR2 expression. Further, BAPTA-AM chelation of intracellular calcium also inhibited
filamin A cleavage, leading to the hypothesis that Wnt5A/ROR2 signaling could cleave filamin A
through activation of calcium-activated proteases, such as calpains. Indeed, WNT5A knockdown
decreased calpain 1 expression, and by inhibiting calpain 1 either pharmacologically or using siRNA, it
decreased cell motility. Our results indicate that Wnt5A activates calpain-1, leading to the cleavage of
filamin A, which results in a remodeling of the cytoskeleton and an increase in melanoma cell motility.
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Abstract
We have previously shown that Wnt5A and ROR2, an orphan tyrosine kinase receptor, interact to
mediate melanoma cell motility. In other cell types, this can occur through the interaction of ROR2
with the cytoskeletal protein filamin A. Here, we found that filamin A protein levels correlated with
Wnt5A levels in melanoma cells. Small interfering RNA (siRNA) knockdown of WNT5A decreased
filamin A expression. Knockdown of filamin A also corresponded to a decrease in melanoma cell
motility. In metastatic cells, filamin A expression was predominant in the cytoplasm, which western
analysis indicated was due to the cleavage of filamin A in these cells. Treatment of nonmetastatic
melanoma cells with recombinant Wnt5A increased filamin A cleavage, and this could be prevented
by the knockdown of ROR2 expression. Further, BAPTA-AM chelation of intracellular calcium also
inhibited filamin A cleavage, leading to the hypothesis that Wnt5A/ROR2 signaling could cleave
filamin A through activation of calcium-activated proteases, such as calpains. Indeed, WNT5A
knockdown decreased calpain 1 expression, and by inhibiting calpain 1 either pharmacologically or
using siRNA, it decreased cell motility. Our results indicate that Wnt5A activates calpain-1, leading
to the cleavage of filamin A, which results in a remodeling of the cytoskeleton and an increase in
melanoma cell motility.
INTRODUCTION
Several recent studies have shown the upregulation of key metastatic markers during the
progression of melanoma and have provided potential molecular targets (Bittner et al., 2000;
Clark et al., 2000; Weeraratna, 2003; Smith et al., 2004). One such marker is Wnt5A, a member
of the noncanonical Wnt pathway, which has been implicated in the pathogenesis of human
cancer (Weeraratna et al., 2002; Kurayoshi et al., 2006; Fernandez-Cobo et al., 2007; MacLeod
et al., 2007; Ripka et al., 2007). Activation of the Wnt5A pathway leads to the release of
calcium from intracellular stores and to the upregulation of target proteins, such as protein
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kinase C (PKC). In melanoma, upregulation of Wnt5A increases cell invasion (Weeraratna et
al., 2002). We have recently shown that this increased invasiveness is due, in part, to an
epithelial-to-mesenchymal transition, accompanied by the upregulation of Snail and Vimentin
(Dissanayake et al., 2007). These findings were consistent with our previous data that showed
that Wnt5A overexpression can cause reorganization of the actin cytoskeleton (Weeraratna et
al., 2002).
The actin cytoskeleton consists of pools of globular monomeric actin (G-actin) that can
reversibly polymerize into filamentous actin (F-actin), thus resulting in alterations in the
viscosity, elasticity, and mechanical resistance of the cell (Popowicz et al., 2006). Bundling
of actin into filopodia (parallel bundles of actin filaments and associated proteins) is important
for directional motility and adhesion of cells (Gupton and Gertler, 2007). Recently, filamin A,
a scaffolding protein that is part of a family of nonmuscle actin-binding proteins, was shown
to be required for filopodia formation, through actin reorganization (Nishita et al., 2006).
Filamin A exists in a dimerized form, containing two hinge regions, which are putative target
sites for calpain cleavage (Feng and Walsh, 2004). Calpains are calcium-dependent
cysteineproteases involved in cytoskeleton remodeling and motility (Potter et al., 1998), and
of the 13 known calpains, only calpains 1 and 2 are considered as ubiquitous calpains (Glading
et al., 2002). Reduced cell migration and disruption of the actin cytoskeleton have been
observed in calpaindeficient embryonic fibroblasts (Dourdin et al., 2001). Interestingly,
calpain 3 has been shown to be dysregulated in melanoma, moving from the nuclei of non-
neoplastic cells to the cytoplasm of malignant cells (Weeraratna et al., 2004).
Filamin A has been shown to mediate Wnt5A-induced cell migration through its interaction
with the orphan tyrosine kinase receptor, ROR2 (Nishita et al., 2006). The suppression of either
ROR2- or filamin A-induced filopodia inhibited cell migration mediated by Wnt5A. As Wnt5A
has been shown to be an important mediator of melanoma progression, we investigated the
relationship between filamin A and Wnt5A in metastatic melanoma.
RESULTS
Filamin A expression is increased in Wnt5A-high melanoma cell lines
Highly metastatic melanoma cells show increased levels of Wnt5A and PO4-PKC (Weeraratna
et al., 2002; Dissanayake et al., 2007). To determine if filamin A was elevated in melanoma
cell lines with high Wnt5A and increased invasiveness, we examined the mRNA and protein
levels of filamin A compared with Wnt5A in melanoma cell lines of differing metastatic
potential. In a recent study, Hoek et al (2006) performed gene expression profiling studies on
a large set of melanoma samples (known as the Mannheim data set). These samples were cell
lines created from primary melanoma biopsies. Gene expression profiling data showed that
these melanomas could be separated into three dominant groups of cell lines (cohorts A, B,
and C). These groups could be characterized by their microphthalmia-associated transcription
factor status, motility, and proliferation. Of these, cohort A and, to a lesser extent, Cohort B
consisted of highly proliferative melanoma cells with low metastatic potential, and cohort C
consisted of weakly proliferative cells with high metastatic potential. Analysis of the
Mannheim data set showed that WNT5A is dramatically upregulated in cohort C as compared
with cohorts A and B (Figure 1a). Bars shown are an average of all samples in each cohort.
Filamin A (FLNA) mRNA was also increased in cohort C, although not as dramatically as
WNT5A (Figure 1b). Western blot analysis was used to validate these observations in a second
set of melanoma cell lines derived from patient samples, and showed a positive correlation
between filamin A and Wnt5A protein expression, in 8 out of 10 cell lines (Figure 1c).
We have previously characterized a panel of melanoma cell lines on the basis of their Wnt5A
status, PKC activity and invasive capacity determined that high Wnt5A and PKC correlate with
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increased metastatic capacity (Weeraratna et al., 2002; Dissanayake et al., 2007). We used
real-time PCR to determine the correlation between FLNA mRNA and WNT5A mRNA. In
these lines, the expression of FLNA mRNA was increased in lines with high WNT5A
expression, and thus increased invasive capacity (Figure 2a). Filamin A protein expression was
also increased in cells with Wnt5A and high levels of PO4-PKC (Figure 2b). Treatment of
Wnt5A-low G-361 cells with recombinant Wnt5A led to an increase in filamin A protein levels
(Figure 2c). To determine whether downregulation of Wnt5A expression affects the levels of
filamin A, small interfering RNA (siRNA) targeted against WNT5A was used. Treatment of
the high Wnt5A-expressing cell line M93-047 with WNT5A siRNA resulted in a significant
decrease in filamin A protein levels, concomitant with a reduction in Wnt5A expression (Figure
2d). These results show a positive correlation between the levels of Wnt5A and filamin A in
metastatic melanoma cells, but it is unclear if Wnt5A directly regulates filamin A, or if an
intermediate step is required.
FLNA knockdown reduces melanoma cell motility
Filamin A has been shown to be essential for filopodia formation, an important event in the
motility and migration of various cell types. To determine if a reduction in filamin A could
lead to decreased motility in melanoma cells, cells were transfected with siRNA against FLNA,
and knockdown of filamin A was observed at 48 hours (Figure 3a). After 48 hours of
transfection with filamin A siRNA and negative control siRNA, cells were subjected to a
wound-healing assay. In highly invasive M93-047 cells transfected with control siRNA, the
wound closed within 24 hours. Knockdown of filamin A prevented closure of the wound
(Figure 3b). Low Wnt5A-expressing G-361 cells, when transfected with negative-control
siRNA, usually take more than 72 hours to completely heal a scratch wound (Figure 3c). When
these negative control-siRNA transfected cells were treated with recombinant Wnt5A, the
wound was completely healed by 48 hours (Figure 3c). Similar to negative control-siRNA-
transfected cells, G-361 cells treated with FLNA siRNA alone also remained open at 48 hours.
Subsequent treatment of FLNA siRNA-transfected cells with recombinant Wnt5A increased
motility slightly, but did not fully rescue the effects of filamin A silencing (Figure 3c). Taken
together, these results show an important role for filamin A in melanoma cell motility and
Wnt5A-induced cell migration.
Wnt5A affects the subcellular distribution of filamin A
One of the key steps in the acquisition of the metastatic phenotype is the reorganization of the
cytoskeleton. Wnt5A overexpression has been shown to affect the expression and organization
of cytoskeletal molecules, such as actin (Weeraratna et al., 2002). We used immunofluorescent
analysis to determine whether Wnt5A expression could similarly affect the subcellular
distribution of filamin A. In low Wnt5A-expressing cells (G-361), filamin A was primarily
localized near the plasma membrane (Figure 4a), whereas in cells with higher levels of Wnt5A
(M93-047 and UACC647), there was an increase in cytoplasmic filamin A (Figure 4a).
Addition of recombinant Wnt5A to G-361 cells resulted in an increase in the expression of
filamin A in the cytoplasm (Figure 4b).
This observation raised the question of whether the cytoplasmic localization of filamin A upon
Wnt5A treatment could be due to its cleavage by cellular proteases. To investigate this
possibility, cell lysates were analyzed using commercial monoclonal antibodies that recognize
either the N- or C-terminal domain of filamin A. Filamin A contains two hinge regions (Gorlin
et al., 1990), and cleavage at hinge 1 generates a 190 kDa fragment that can be detected using
an antibody that recognizes the N-terminal of this protein. Cleavage at hinge 2 results in a ~90
kDa fragment, which can be detected with an antibody directed against the C-terminal. In low-
Wnt5A, nonmetastatic G361 cells, there is little cleavage at either hinge 1 or hinge 2 as
compared with the highly metastatic lines (Figure 4c). However, treatment of G-361 cells with
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recombinant Wnt5A increased the cleavage of filamin A in a dose-dependent manner (Figure
4d). These results indicate that cleavage of filamin A occurs at both hinge regions and is
inducible by Wnt5A, which may explain the intracellular redistribution of filamin A in response
to Wnt5A treatment.
Cleavage of filamin A is mediated by calpain 1 in melanoma cell lines
Calpains are calcium-dependent proteases that can cleave filamin A at both hinge regions (Loy
et al., 2003). At present, there are 13 known human calpains (CAPN1–7, 9–11, 13, and 15),
but only calpains 1 and 2 are considered as ubiquitous (Glading et al., 2002). We show here
that Wnt5A promotes cleavage of filamin A. It has been reported previously that Wnt5A can
increase the intracellular concentrations of calcium (reviewed by Kühl et al., 2000). In addition,
we have recently shown that Wnt5A requires ROR2 to activate the Ca2+/PKC pathway and
mediate the motility of melanoma cells (O’Connell et al., unpublished data). We hypothesized
that Wnt5A signaling through ROR2 increases calcium release from the endoplasmic
reticulum, thereby activating calpain, which in turn cleaves filamin (Figure 5a). We tested the
first step in this hypothesis by knocking down ROR2 using siRNA. ROR2 knockdown in
Wnt5A-high cells resulted in a decrease in filamin A cleavage (Figure 5b). The use of 1,2- Bis
(2-aminophonoxy)ethane-N,N,N′,N′-tetraacetic acid tetrakis-(acetoxymethylester) (BAPTA-
AM) as a calcium chelator in these cells also decreased filamin cleavage (Figure 5c), implying
that both ROR2 and calcium are required for Wnt5A-mediated filamin A cleavage, potentially
through the activation of calpains. To investigate this possibility, endogenous mRNA levels
of several calpains were determined in low and high Wnt5A-expressing melanoma cell lines
using real-time PCR (data not shown). CAPN1 and 2 were most abundantly expressed at the
mRNA level. Western analysis showed that, of these, only CAPN1 protein levels correlated
with Wnt5A expression (Figure 5d), and that the knockdown of WNT5A resulted in a decrease
in CAPN1 (Figure 5e).
Next, we investigated the effect of a cell-permeable calpain inhibitor (calpain inhibitor III) on
the cleavage of filamin A in Wnt5A-high cells. Treatment of cells with calpain inhibitor for
24 hours caused a marked reduction in filamin A fragmentation (Figure 5f). Wnt5A levels were
unaffected as would be expected, if calpain signaling is truly downstream of Wnt5A. To
determine whether cellular redistribution of filamin A could result from the inhibition of
calpain activity, indirect immunofluorescent analyses were performed using the N-terminal
filamin antibody. Cells were costained for F-actin using Phalloidin. Filamin A
immunoreactivity was observed throughout the cytoplasm of the cell, and actin was
polymerized at the leading edge of these highly invasive cells (Figure 5g). Furthermore, there
was almost no colocalization of actin and filamin A (Figure 5g, white arrow, Figure S1A).
Upon pretreatment of these cells with calpain inhibitor III, filamin A clearly colocalized with
cortical actin at the cell periphery (Figure 5g, yellow arrow, Figure S1B), confirming that
calpain cleavage is necessary for the cytoplasmic redistribution of filamin A. Taken together,
these data indicate that Wnt5A signaling through ROR2 activates calcium and is required for
the expression and activation of CAPN1, and the subsequent cleavage of filamin A.
Calpain inhibition reduces motility in melanoma cell lines
To determine if the cleavage of filamin A was necessary for melanoma cell motility, wound
healing assays were performed in the presence or absence of calpain inhibitor III for 24 hours.
The results clearly showed a dose-dependent reduction in motility in the two Wnt5A-high lines
M93-047 and UACC647 (Figure 6a). SiRNA-mediated gene silencing was then used to
specifically target CAPN1. This resulted in a significant inhibition of CAPN1 expression as
compared with negative control siRNA (Figure 6b). Knockdown of CAPN1 expression delayed
wound closure by several hours in both M93-047 and UACC647 cell lines, when compared
with cells transfected with control siRNA (Figure 6c).
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DISCUSSION
We have shown previously that Wnt5A increases melanoma metastasis through increases in
PKC and affects cytoskeletal reorganization (Weeraratna et al., 2002; Dissanayake et al.,
2007). We have also shown recently that Wnt5A requires ROR2 to signal effectively, and the
knockdown of ROR2 can abrogate Wnt5A-mediated melanoma cell motility (O’Connell et
al., unpublished data). In osteoblasts, ROR2 interacts physically with filamin A (Flanagan et
al., 2001). We show here that Wnt5A signaling, through ROR2, can increase filamin A
expression. This interaction requires a mechanism involving the activation of calcium-
activated proteases, specifically calpain 1, and to our knowledge this is unreported previously.
Wnt5A can increase both PKC activity and the levels of intracellular calcium (Kühl et al.,
2000). We have shown previously that other calcium-activated proteins (such as calmodulin-
activated kinase II) can be increased upon increased Wnt5A signaling (Dissanayake et al.,
2007). Calpains are a family of calcium-dependent, non-lysosomal cysteine proteases that
cleave cytoskeletal proteins, such as filamin A (Potter et al., 1998; Feng and Walsh, 2004).
The correlation between calpain 1 and Wnt5A protein expression suggests that calpain 1 is a
Wnt5A-inducible protein whose upregulation may be responsible for the increased levels of
cleaved filamin A in response to Wnt5A signaling. We propose that in nonmetastatic melanoma
cells with little Wnt5A signaling, where the levels of calcium are low, calpain 1 signaling is
minimal, whereas upon activation of the Wnt5A/ROR2 signaling pathway, calcium influx
increases and calpain 1 becomes activated, resulting in the subsequent cleavage of filamin A.
This is supported by our data indicating that filamin A cleavage can be inhibited by ROR2
siRNA, as well as by chelation of calcium by BAPTA-AM. Furthermore, we show that WNT5A
knockdown decreases calpain 1 expression, and filamin A cleavage and expression.
Blocking calpain activity reduces melanoma cell motility, possibly due to the lack of filamin
A cleavage and ensuing intracellular redistribution. These results support earlier findings that
calpain-mediated cleavage of cytoskeletal proteins is essential for motility and invasiveness.
For example, it has been reported that calpains are required for normal osteoclast function and
that reduction of calpains leads to a decrease in motility (Marzia et al., 2006). In renal cell
cancer, calpain 1 expression has been shown to correlate with advanced disease and poorer
outcome (Braun et al., 1999). In melanoma, specifically, calpains have been shown to be
important in the degradation of p27kip1, the loss of which is associated with poorer outcome
for melanoma (Delmas et al., 2003). Another interesting observation is that calpains are
involved also in regulating melanin biosynthesis, potentially through the degradation of
tyrosinase (Ohguchi et al., 2005). The reason that this is particularly intriguing is that recent
data from our laboratory suggest that Wnt5A overexpression results in a decrease in both
melanin production and the expression of many markers associated with melanogenesis
(Dissanayake et al., 2008). Although we show that at least some of these markers are regulated
through Wnt5A/PKC activation of STAT3, and subsequent STAT3-mediated inhibition of the
transcription factors PAX3 and SOX10, not all melanogenic proteins are under the control of
these factors. It is probable that the Wnt5A-mediated activation of calpain-1, and the
subsequent degradation of other melanogenic proteins, may also play a complementary role in
the regulation of melanogenesis. As many of the proteins involved in melanogenesis (for
example, MART-1, GP100) can act as antigens for tumor-infiltrating immune cells (Kawakami
et al., 1998), the downregulation of these antigens by tumor cells may result in increased tumor
aggression.
To our knowledge, the findings that filamin A expression correlates with levels of Wnt5A in
melanoma cell lines and that a reduction of filamin A decreases the metastatic potential of these
cells have not been reported previously. Furthermore, Wnt5A can induce calpain-dependent
cleavage of filamin A, an essential step in promoting cell motility and invasiveness in
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melanoma cell lines. Targeting Wnt5A in conjunction with any of these downstream markers
could have significant implications for melanoma therapy.
MATERIALS AND METHODS
Analysis of the Mannheim data set
The Mannheim data is publicly available from NCBI’s gene expression omnibus
(www.ncbi.nlm.nih.gov/geo) under GEO Series accession no. GSE4845. This data set was
generated from microarray analysis of 45 primary cultures of melanoma biopsies, using
Affymetrix HGU133 microarray chips. Analysis of the data set for expression of WNT5A and
FLNA was performed using a Student’s two-tailed t-test (assuming equal variance) to
determine statistical significant between cohorts.
Cell culture
Cells were cultured in T-25 tissue culture flasks and expanded in T-75 flasks (Corning,
Corning, NY). UACC903, M93-047, UACC647, and Franklin Square cell lines were
maintained in RPMI (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum
(Invitrogen), 100Uml−1 penicillin and streptomycin, and 4mM L-glutamine. G-361 cells were
maintained in McCoy’s (Invitrogen) supplemented with 10% fetal bovine serum, 100Uml−1
penicillin and streptomycin, and 4mM L-glutamine. All cell lines were cultured at 37°C in 5%
CO2, and the medium was replaced every 2–3 days as needed.
Wnt5A and calpain inhibitor treatment
For experiments requiring treatment, cells were incubated with 50–200 ng ml−1 of recombinant
mouse Wnt5A (R&D Systems, Minneapolis, MN) for 16 hours or 0.5, 1, or 10 μM of calpain
inhibitor III (Sigma Aldrich, St. Louis, MO) for 24 hours.
siRNA transfection
Cells were transfected with high performance (HP)-validated negative control (CTRL), FLNA,
and CAPN1 siRNA (200 nmol, Qiagen, Valencia, CA) using Lipofectamine (Invitrogen) for
48 hours as described previously (Dissanayake et al., 2007). Sequences for siRNA were as
follows: CTRL: sense, r(UUCUCCGAACGUGUCG UCACGU)dTdT; antisense, r
(ACGUGACACGUUCGGAGAA)dTdT; FLNA: sense, r(GGAAGAAGAUCCAGCAGAA)
dTdT; antisense, r(UUCUGCUGGAUCUUCUUCC)dGdG; CAPN1: sense, r(CCACG
GAACUGCUGUCAAA)dTdT; antisense, r(UUUGACAGCAGUUCC GUGG)dGdG.
These siRNAs are designed with unequal stabilities of the 3′ and 5′ bases, to reduce the risk of
off-target effects. Details can be found at the Qiagen website:
http://www1.qiagen.com/products/genesilencing/hponguardsirnadesign.aspx.
Wound-healing assay
Cells were seeded at 1×105 cells per well in 24-well plates coated with fibronectin (BD
Biosciences, San Jose, CA). Once confluent, a 200 μl tip (PGC Scientifics) was heat-sealed,
and one horizontal and one vertical scratch was made. Images of the same field were taken at
0, 12, 24, 48, and 72 hours, as required, on a light microscope (Zeiss) using phased light at a
gain of 1.
Immunofluorescence
Cells were seeded at 5×105 cells per well (G-361) and 3×105 cells per well (UACC903 and
M93-047) into one-well chamber slides (Lab-Tek, Campbell, CA) and incubated overnight at
37°C, 5% CO2, in a humidified environment. Cells were fixed in ice-cold 95% methanol for
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20minutes at room temperature, washed in phosphate-buffered saline, and blocked using
sterile-filtered blocking buffer (0.2% Triton X-100, 0.2% BSA, 0.2% casein, 0.2% gelatin, and
0.02% sodium azide) for 1 h at room temperature. Filamin A primary antibody (1:100, RDI,
Concord, MA) was added in blocking buffer and slides were incubated overnight at 4°C. Cells
were then washed in phosphate-buffered saline and treated with Alexa Fluor-555 secondary
antibody (1:1,000, Invitrogen) in blocking buffer for 1 h at room temperature. For F-actin
staining, cells were fixed in 4% paraformaldehyde and stained with Phalloidin-488
(Invitrogen). Next, cells were washed in phosphate-buffered saline and mounted in Prolong
Gold antifade reagent containing 4,6-diamidino-2-phenylindole (Invitrogen) and cured for 24
hours at room temperature in the dark. Images were taken using a Zeiss Meta 510 confocal
microscope.
RNA extraction, cDNA synthesis, and real-time PCR
RNA was extracted using Trizol (Invitrogen) and an RNeasy Mini kit (Qiagen), and from 1
μg of RNA, cDNA was synthesized as described previously (Dissanayake et al., 2007). Gene
expression was quantified using the SYBR green method of real-time PCR and mRNA levels
were compared with standard curves and normalized to 18S mRNA following the absolute
quantitation method. PCRs were performed in triplicate with Universal 18S primers (Ambion,
Austin, TX) or 100 nM of each gene-specific primer. Primers are included in Table S1. Real-
time PCR was performed on an ABI Prism 7,300 sequence detection system using the following
conditions: 50°C for 2 minutes, 95°C for 10 minutes, 40 cycles of 95°C for 15 seconds, and
60°C for 1 minute.
SDS-PAGE and western blotting
Cells were lysed as described previously (Dissanayake et al., 2007). A total of 50 μg of protein
was run on a 4–20% Tris-glycine gel (Invitrogen), transferred, and blocked as described
previously (Dissanayake et al., 2007). Primary antibodies were incubated overnight at 4°C as
follow: anti-filamin A (1:1,000, RDI), N-terminal anti-filamin A (1:1,000, Chemicon,
Billerica, MA), C-terminal anti-filamin A (1:1,000, Chemicon), biotin-conjugated anti-Wnt5A
(1:100, R&D Systems), PO4-PKC (1:1,000, Cell Signaling, Danvers, MA), and β-tubulin
(1:1,000, Cell Signaling). Membranes were washed in TBST, and the appropriate secondary
antibody was added in 5% milk/TBST for 1 h at room temperature with agitation. Membrane
was washed in TBST and developed using ECL plus (Amersham Biosciences, GE
Healthsciences, Piscataway, NJ).
Densitometry
Images were saved as Tiff files, inverted, and integrated density was analyzed. Densitometry
was performed using ImageJ software (NIH) and values were normalized to β-tubulin.
Statistical analysis
A Student’s t-test was performed when required in at least three independent experiments.
Significance was designated as *P<0.05 and **P<0.01.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Abbreviations
PKC  
protein kinase C
siRNA  
small interfering RNA
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Figure 1. Filamin A expression is increased in primary melanoma cell lines with high Wnt5A
expression
(a) WNT5A and (b) FLNA mRNA expression in the three cohorts of the Mannheim data set.
Cohorts A (n=19) and B (n=10) were considered low metastatic cell lines, whereas cohort C
(n=16) was highly metastatic. Their metastasis rates inversely correlate with their proliferation
as indicated in the table below the graphs. FLNA was significantly correlated with WNT5A
(**P<0.01). Bars represent averages of all patients in each cohort. (c) Western blot analysis
was performed on 10 melanoma patient cell lines to detect filamin A and Wnt5A, and confirmed
that filamin A protein expression and Wnt5A expression are correlated at the protein level as
well. β-Tubulin was used as a loading control.
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Figure 2. Wnt5A expression affects that of filamin A
(a) Real-time PCR analysis of WNT5A and FLNA mRNA in G-361, UACC903, M93-047, and
UACC647 cell lines, normalized to 18S levels. Error bars are represented as SEM, with values
of *P<0.05 and **P<0.01. In G361 cells with low metastatic capacity, WNT5A and FLNA
levels are low as compared with the other three metastatic cell lines. (b) Total protein was
isolated for western blot analysis of filamin A, PO4-PKC, and Wnt5A in all cell lines. Again,
G361 cells express lower levels of all of these proteins, but the expression of filamin A and
Wnt5A can be increased significantly upon rWnt5A treatment. (c) High Wnt5A-expressing
M93-047 cells were transfected with either control (CTRL) or WNT5A siRNA for 48 hours.
(d) Total protein was isolated for western blot analysis of Wnt5A and filamin A expression,
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and showed decreases in filamin A occurring upon Wnt5A knockdown. β-Tubulin was used
as a loading control.
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Figure 3. Filamin A is required for motility of melanoma cell lines
(a) M93-047 cells were transfected with control or FLNA siRNA for 48 hours. Total protein
was isolated for western blot analysis of filamin A. β-Tubulin was used as a loading control.
(b) Highly metastatic M93-047 cells were transfected with control or FLNA siRNA for 48
hours and then subjected to a wound-healing assay for 24 hours. Images were taken until closure
of the scratch wound (24 hours), and FLNA knockdown inhibited the motility of melanoma
cells. (c) Low metastatic G-361 cells were transfected with control or FLNA siRNA for 48
hours, and then left untreated or treated with recombinant Wnt5A for the duration of the wound-
healing assay (48 hours). Wnt5A treatment could not completely rescue the decrease in motility
upon FLNA knockdown. Images were taken until closure of the scratch (48 hours).
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Figure 4. Wnt5A increases filamin A cleavage
(a) The expression and localization of filamin A (red) was examined in melanoma cell lines
of differing metastatic potential using immunofluorescent confocal microscopy. Filamin A is
found in a regular pattern around the periphery of the cell in G361 cells (low metastatic
potential), but is more cytoplasmic and irregular in the cell lines with a higher metastatic
potential. (b) Treatment of G-361 cells with recombinant Wnt5A for 16 hours resulted in a
redistribution of filamin A to the cytoplasm of the cells akin to the lines with higher metastatic
capacity. Scale bar=20 μm. (c) Total protein lysates from G-361, UACC903, M93-047, and
UACC647 cell lines were analyzed by western blot for the presence of filamin A cleavage
fragments. Filamin A cleavage fragments were identified as 190 kDa (N-terminal) and 90 kDa
(C-terminal) bands, and cleavage was indeed increased in cell lines with higher metastatic
capacity. β-Tubulin was used as a loading control. (d) G-361 cells were treated with increasing
amounts of recombinant Wnt5A for 16 hours and total protein was isolated for western blot
analysis of the 190 and 90 kDa N-terminal cleavage fragment. β-Tubulin was used as a loading
control.
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Figure 5. Calpain 1 plays a role in Wnt5A-mediated cleavage of filamin A
(a) Schematic hypothesis of Wnt5A-mediated filamin A cleavage: Wnt5A binds to ROR2
causing the intracellular release of calcium, which can increase calpain activity, resulting in
an increase in filamin A cleavage. (b) SiRNA knockdown of ROR2 prevents filamin A cleavage
in Wnt5A-high cells. (c) BAPTA chelation of intracellular calcium decreases the levels of
filamin A cleavage in a dose-dependent manner. (d) Calpain 1, but not calpain 2, protein
expression correlates with that of Wnt5A and, thus, to increased invasive potential. (e)
Knockdown of Wnt5A decreases calpain 1 expression. (f) M93-047 cells were treated with
increasing concentrations of calpain inhibitor III. Western blot analysis of Wnt5A and filamin
A N-terminal cleavage (190 kDa) were performed, and showed that filamin A cleavage is
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attenuated in the presence of calpain inhibitor. β-Tubulin was used as a loading control. (g)
Treatment of M93-047 cells with 10 μM of calpain inhibitor III results in a redistribution of
filamin A (red staining) from the cytosol to the periphery of the cell. In calpain-inhibitor-treated
cells, filamin A also colocalizes with actin (green). Scale bar=20 μm. All experiments shown
here were performed with multiple Wnt5A-high cell lines, but in the interest of space, only
M93-047 data is shown.
O’Connell et al. Page 16
J Invest Dermatol. Author manuscript; available in PMC 2010 January 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 6. Inhibition of CAPN1 decreases motility in highly metastatic melanoma cell lines
(a) M93-047 and UACC647 cells were treated with increasing amount of calpain inhibitor III,
then subjected to a wound-healing assay for 24 hours. Calpain inhibition decreased the motility
of melanoma cells. (b) M93-047 and UACC647 cells were treated with CTRL or CAPN1
siRNA for 48 hours. Total RNA was isolated and real-time PCR analysis of CAPN1 expression
was performed. Levels were normalized to 18S expression. Error bars are represented as SEM,
with values of **P<0.01. (c) M93-047 and UACC647 cells were treated with CTRL or CAPN1
siRNA for 48 hours, then subjected to a wound-healing assay for 12 hours. Calpain 1 inhibition
by siRNA inhibited the motility of melanoma cells.
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